K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.82 CAD 0.52% Market Closed
Market Cap: 578.8m CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one GUD stock under the Base Case scenario is 5.04 CAD. Compared to the current market price of 5.82 CAD, Knight Therapeutics Inc is Overvalued by 13%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GUD Relative Value
Base Case
5.04 CAD
Overvaluation 13%
Relative Value
Price
K
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
85
vs Industry
58
Median 3Y
1.7
Median 5Y
2.3
Industry
2.4
Forward
1.4
More Details
52.3
P/E
P/E
Price to Earnings
52.3
vs History
17
vs Industry
2
Median 3Y
-27.1
Median 5Y
-18.5
Industry
21
Forward
102.5
More Details
63.8
P/OCF
P/OCF
Price to OCF
63.8
vs History
3
vs Industry
26
Median 3Y
15.3
Median 5Y
14.9
Industry
16.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
19
Median 3Y
16.1
Median 5Y
-3.2
Industry
24
More Details
0.7
P/B
P/B
Price to Book Value
0.7
vs History
63
vs Industry
67
Median 3Y
0.7
Median 5Y
0.7
Industry
2
More Details
1.2
EV/S
EV/S
Enterprise Value to Sales
1.2
vs History
85
vs Industry
66
Median 3Y
1.3
Median 5Y
1.4
Industry
2.6
Forward
1.1
More Details
2.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.7
vs History
80
vs Industry
63
Median 3Y
2.9
Median 5Y
3.3
Industry
5.1
More Details
8.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.7
vs History
63
vs Industry
38
Median 3Y
8.7
Median 5Y
9.7
Industry
12.6
Forward
8.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
6
Median 3Y
-32.4
Median 5Y
-26.6
Industry
16
Forward
19.1
More Details
49.5
EV/OCF
EV/OCF
Enterprise Value to OCF
49.5
vs History
3
vs Industry
33
Median 3Y
11.6
Median 5Y
11
Industry
14.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
5
Median 3Y
21.1
Median 5Y
8.8
Industry
17.6
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
34
vs Industry
69
Median 3Y
0.6
Median 5Y
0.6
Industry
1.8
More Details

Multiples Across Competitors

GUD Competitors Multiples
Knight Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Knight Therapeutics Inc
TSX:GUD
578.8m CAD 1.6 52.3 8.7 -560.6
US
Eli Lilly and Co
NYSE:LLY
688.1B USD 14 62 33.4 36.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
368.7B USD 4.1 16.9 12.4 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 6.8 19.7 13.6 15.7
CH
Roche Holding AG
SIX:ROG
208.6B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
183.9B CHF 4.2 17.4 10.3 13.8
UK
AstraZeneca PLC
LSE:AZN
162.6B GBP 4 28.4 130.8 197.3
US
Merck & Co Inc
NYSE:MRK
195.2B USD 3.1 11.2 8.4 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
134.4B USD 2.2 17 7.4 10.4
P/E Multiple
Earnings Growth PEG
CA
K
Knight Therapeutics Inc
TSX:GUD
Average P/E: 27.8
52.3
23%
2.3
US
Eli Lilly and Co
NYSE:LLY
62
50%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.9
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.7
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
17.4
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.4
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.2
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
K
Knight Therapeutics Inc
TSX:GUD
Average EV/EBITDA: 394.7
8.7
-2%
N/A
US
Eli Lilly and Co
NYSE:LLY
33.4
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
13%
1
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
CH
Novartis AG
SIX:NOVN
10.3
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.4
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
K
Knight Therapeutics Inc
TSX:GUD
Average EV/EBIT: 1 866.9
Negative Multiple: -560.6
20%
N/A
US
Eli Lilly and Co
NYSE:LLY
36.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
CH
Novartis AG
SIX:NOVN
13.8
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.3
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
10%
1

See Also

Summary
GUD intrinsic value, competitors valuation, and company profile.
DCF Valuation
GUD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GUD stock valuation using valuation multiples.
Wall Street Estimates
GUD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GUD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 257,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.